News Releases

Nautilus Biotechnology to Participate in the Investor Summit Group Virtual Conference

SEATTLE, March 24, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the Investor Summit Group Virtual Conference.

Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform

• Baylor selects the Nautilus Voyager™ Platform, now available through Early Access Program, for development of a first-in-class computational multi-omics toolkit • NIH-funded project leverages collaborators’ expertise in single-molecule proteomics and protein isoform quantification to advance

Nautilus Biotechnology Appoints Proteomics Commercial Leader Amber Faust as Vice President of Sales

Veteran sales leader with proven proteomics and life sciences track record from Olink and SomaLogic joins Nautilus to accelerate commercial progress of its Voyager Platform SEATTLE, March 02, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering single-molecule

Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2025 Financial Results

SEATTLE, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2025.

Nautilus Biotechnology Unveils Voyager Platform, Enabling Single-Molecule Iterative Mapping, at US HUPO 2026

• Revealed core proteomics instrument during US HUPO 2026 following successful field evaluation at the Buck Institute for Research on Aging • Commercial launch expected to initiate in late 2026, marking a major milestone for next-generation proteomics • Researchers invited to apply to the Early

Nautilus Biotechnology to Participate in the TD Cowen 46th Annual Health Care Conference

SEATTLE, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the TD Cowen 46 th Annual Health Care Conference.

Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the fourth quarter and full year 2025 before market open on Thursday,

Nautilus Biotechnology and Weill Cornell Medicine-Qatar Collaborate with The Michael J. Fox Foundation to Advance Single-Molecule Proteomics Research in Parkinson’s Disease

• Support from The Michael J. Fox Foundation for Parkinson’s Research to advance critical research into Parkinson’s disease biology  • Nautilus’ development of a single-molecule assay for measuring alpha-synuclein proteoforms is its latest application of Iterative Mapping method to uncover new

Nautilus Biotechnology Launches Early Access Program for Novel Single-Molecule Proteomics Platform, Starting with Tau Proteoforms Assay

Early Access Program participants receive exclusive use of Nautilus’ Iterative Mapping method, initially through a validated tau proteoforms assay, with the potential to accelerate Alzheimer’s and neurodegenerative disease research SEATTLE, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology,